Equities analysts expect PetIQ Inc (NASDAQ:PETQ) to report $52.07 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for PetIQ’s earnings. The highest sales estimate is $53.90 million and the lowest is $51.20 million. The business is scheduled to issue its next quarterly earnings report on Monday, February 19th.
According to Zacks, analysts expect that PetIQ will report full year sales of $52.07 million for the current fiscal year, with estimates ranging from $266.40 million to $268.70 million. For the next fiscal year, analysts expect that the business will report sales of $466.83 million per share, with estimates ranging from $462.20 million to $469.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover PetIQ.
PETQ has been the topic of several research analyst reports. Zacks Investment Research cut PetIQ from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 12th. Jefferies Group reissued a “buy” rating and issued a $27.00 price objective on shares of PetIQ in a research note on Monday, January 8th. Finally, BidaskClub raised PetIQ from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. PetIQ currently has a consensus rating of “Buy” and a consensus price target of $26.83.
Institutional investors have recently bought and sold shares of the business. American International Group Inc. purchased a new stake in PetIQ during the third quarter worth $131,000. Keeler Thomas Management LLC purchased a new stake in PetIQ during the fourth quarter worth $131,000. Wells Fargo & Company MN purchased a new stake in PetIQ during the third quarter worth $204,000. California State Teachers Retirement System purchased a new stake in PetIQ during the third quarter worth $320,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in PetIQ during the third quarter worth $344,000. Institutional investors own 56.57% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/petiq-inc-petq-expected-to-post-quarterly-sales-of-52-07-million-2.html.
PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.